All In Biotech

NDA 208434 · Hoffmann-La Roche

Alecensa

Alectinib Hydrochloride · Oral

NovelBreakthrough therapyAccelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Aug 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Dec 11, 2015

Approved uses

4

Original approval plus efficacy supplements

Registered trials

77

14 Phase 3, 20 recruiting

FAERS reports

7,388

4,065 serious, 951 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 21, 2026.

ALECENSA is a kinase inhibitor indicated for: adjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors ≥ 4 cm or node positive) as detected by an FDA-approved test. ( 1.1 ) treatment of adult patients with ALK-positive metastatic NSCLC as detected by an FDA-approved test. ( 1.2 ) 1.1 Adjuvant Treatment of Resected ALK-Positive Non-Small Cell Lung Cancer (NSCLC) ALECENSA is indicated as adjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors ≥ 4 cm or node positive), as detected by an FDA-approved test [see Dosage & Administration (2.1) ]. 1.2 Treatment of Metastatic ALK-Positive NSCLC ALECENSA is indicated for the treatment of adult patients with ALK-positive metastatic NSCLC as detected by an FDA-approved test [see Dosage & Administration (2.1) ] .

Mechanism: Alectinib is a tyrosine kinase inhibitor that targets ALK and RET. In nonclinical studies, alectinib inhibited ALK phosphorylation and ALK-mediated activation of the downstream signaling proteins STAT3 and AKT, and decreased tumor cell viability in multiple cell lines harboring ALK fusions, amplifications, or activating mutations. The major active metabolite of alectinib, M4, showed similar in vitro potency and activity. Alectinib and M4 demonstrated in vitro and in vivo activity against multiple mutant forms of the ALK enzyme, including some mutations identified in NSCLC tumors in patients...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 11, 2026 Supplement 16 · Efficacy OrphanLetterLabel
  • Apr 18, 2024 Supplement 15 · Efficacy · priority review OrphanLetterReviewLabel
  • Nov 6, 2017 Supplement 3 · Efficacy · priority review Breakthrough therapyLabelLetter
  • Dec 11, 2015 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanReviewSummary ReviewLabel
1 products under this application
  • ALECENSA · ALECTINIB HYDROCHLORIDE EQ 150MG BASE · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Alectinib" as an intervention, any sponsor and status, largest first.

All 77 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death718
  • fatigue526
  • no adverse event472
  • off label use472
  • constipation455
  • rash267
  • dyspnoea240
  • disease progression216
  • weight increased213
  • myalgia212
  • asthenia200
  • peripheral swelling180

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2016125
2017255
2018529
2019589
2020878
2021704
2022759
2023743
20241,856
2025541
2026409

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Alecensa (Alectinib HCl)

2024 spending

$247M

Beneficiaries

1,906

14,597 claims

Per beneficiary

$129,435

$76.48 per unit

View as table
YearSpending
2020$105,142,346
2021$125,219,804
2022$153,932,232
2023$185,955,638
2024$246,703,794

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 120 on PubMed

Sponsor: Roche (Genentech)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.